clopidogrel bioequivalence - PD endpoint [Design Issues]

posted by lukamar – Poland, 2009-01-19 11:33 (6366 d 07:15 ago) – Posting: # 3059
Views: 9,760

Hi again
Please let me ask again - any ideas how to deal with clopidogrel?
I know that internet forum is not best place for sharing such a valuable knowledge, but any kind of info will be highly appreciate.
Is "sorry - we can not measure active metabolite" the only rationale for performing BE study on Clopidogrel PK only?
I know that in theory formulation does not affect human metabolism, but if so, where idea of measuring metabolites comes from at first place?
I hope that I expressed my doubts clearly enough :-)
Best regards
Łukasz


Edit: Full quote removed. Please see this post! Helmut

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
162 visitors (0 registered, 162 guests [including 25 identified bots]).
Forum time: 19:48 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5